<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158898</url>
  </required_header>
  <id_info>
    <org_study_id>TPI ASM8-207</org_study_id>
    <nct_id>NCT01158898</nct_id>
  </id_info>
  <brief_title>Efficacy of TPI ASM8 During a 14-Day Allergen Challenge</brief_title>
  <official_title>A Double-Blind,Randomized, Placebo-controlled, 3-Way Cross Over Study to Evaluate the Efficacy and Safety of 14 Days TPI ASM8 in Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmaxis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, 3-way crossover trial to evaluate the
      efficacy and safety of two different doses of inhaled TPI ASM8 administered daily for 14 days
      for the treatment of allergic asthma and allergen-induced asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two doses of TPI ASM8 will be compared to placebo and look at the effect on asthmatic
      responses after an allergen challenge during a 3-way cross over design. Sputum inflammation ,
      mRNA gene expression on target receptors, ECP , biomarkers of mast cells activation et PK
      profile will be studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the AUC of the late asthmatic response (LAR) between treatments and placebo</measure>
    <time_frame>Day 14 (Between 3-7 hr post-AIC)</time_frame>
    <description>The area under the curve fo the late asthmatic response(% fall in FEV1)(between 3-7 hrs post allergen challenge) will be compared between the 2 doses of TPI ASM8 and the placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the early and late asthmatic responses between active treatments and placebo after 14 days treatment</measure>
    <time_frame>Day 14</time_frame>
    <description>Compare the % fall in FEV1 during the EAR and the LAR post-allergen challenge on Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the Methacholine Hyperresponsiveness (PC20) between treatment pre and post allergen challenge</measure>
    <time_frame>Day 13 and Day 15 (Pre &amp; post AIC)</time_frame>
    <description>We will compare the PC20( provocative concentration of methacholine) that cause a 20% fall in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ASM8 on mast cells (as measured by specific biomarkers)</measure>
    <time_frame>Day 14 (pre, post and and peri-AIC)</time_frame>
    <description>The leukotriene E4 and 9-11B PGF2 wil be measured in urine and plasma to determine the level of mast cells activation following the allergen challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum inflammation indicators (Eos, neutrophils, etc.)</measure>
    <time_frame>Day 14 and Day 15</time_frame>
    <description>We will measure the levels of total cell counts and the differential to evaluate the degree of inflammation between treatments and placebo.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>TPI ASM8 low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPI ASM8 high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPI ASM8</intervention_name>
    <description>ASM8 4mg/mL (low dose) daily for 14 days by inhalation</description>
    <arm_group_label>TPI ASM8 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPI ASM8</intervention_name>
    <description>ASM8 4mg/mL (high dose) daily for 14 days by inhalation</description>
    <arm_group_label>TPI ASM8 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPI ASM8</intervention_name>
    <description>Placebo PBS solution daily for 14 days by inhalation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild asthma, male and female aged 18-55 y.old

          -  Steroid-naive, non-smoker

          -  Dual responders

        Exclusion Criteria:

          -  Any chronic disease(unstable)

          -  Immunosuppressed, recent or ongoing steroid intake

          -  Methacholine PC 20 &gt; 16 mg/mL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul O'Byrne, MD</last_name>
    <role>Study Chair</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rene Pageau, M.Sc Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Pharmaxis Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis-Philippe Boulet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Laval, Quebec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Leigh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gail M Gauveau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Fitzgerald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vancouver Coastal Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Research Innovation Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Coastal Health Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laval Centre de Pneumologie Chest Division</name>
      <address>
        <city>Quebec</city>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild to moderate asthma</keyword>
  <keyword>Allergen inhalation challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

